Together we can develop treatments urgently needed to protect our health now, and the health of future generations.
Sexually Transmitted Infections (STIs) are worryingly on the increase, particularly among young people aged 15 to 24 years. Gonorrhoea is one of the most common STIs, with 87 million new infections worldwide every year. World Sexual Health Day on September 4 reminds us to highlight the critical need for prevention and treatment and to reflect on GARDP’s work towards a new and more effective and affordable treatment for gonorrhoea.
Professor Sithembiso Velaphi is head of paediatrics at the Chris Hani Baragwanath Academic Hospital in Soweto, South Africa. The hospital, which is the largest in Africa, is one of 19 sites across 11 countries which is involved in one of the largest ever studies on the care of babies with sepsis. GARDP is running the study together with St George’s University of London and the Paediatric Infectious Disease Network (Penta). GARDP asked Professor Velaphi, who specializes in neonatology, eight questions about his work and his passion for the field.
Paula Dixon, Lab Manager at the Division of Infectious Diseases at the University of Alabama at Birmingham, prepares a culture of gonorrhoea for testing. Dixon’s lab serves as a repository for all sites involved in GARDP’s zoliflodacin trial. Gonorrhoea is an infection caused by the Neisseria gonorrhoeae bacterium. It spreads through vaginal, anal and […]
Henry De Vries, Principle Investigator in the Netherlands for the trial of zoliflodacin, talks about the rise of drug-resistant gonorrhoea and the importance of developing new treatments.
Globally, sepsis is a leading cause of death in children under 5. This unacceptable and preventable health crisis is worsened by drug resistance. Up to 40% of bacterial infections in newborns are resistant to standard treatments and more than 214,000 babies die each year from resistant infections. It is time to put children first in the fight against antibiotic resistance.